Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study
Cancer Research and Treatment · 2024
DOI: 10.4143/crt.2024.104 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Tingting Chen und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovat…. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
The risk stratification of pediatric anaplastic large cell lymphoma (ALCL) has not been standardized. In this study, new risk factors were included to establish a new risk stratification system for ALCL, and its feasibility in clinical practice was explored.Materials and Methods On the basis of the non-Hodgkin’s lymphoma Berlin–Frankfurt–Munster 95 (NHL-BFM-95) protocol, patients with minimal disseminated disease (MDD), high-risk tumor site (multiple bone, skin, liver, and lung involvement), and small cell/lymphohistiocytic (SC/LH) pathological subtype were enrolled in risk stratification. Patients were treated with a modified NHL-BFM-95 protocol combined with an anaplastic lymphoma kinase inhibitor or vinblastine (VBL).
Results
A total of 136 patients were enrolled in this study. The median age was 8.8 years. The 3-year event-free survival (EFS) and overall survival of the entire cohort were 77.7% (95% confidence interval [CI], 69.0% to 83.9%) and 92.3% (95% CI, 86.1% to 95.8%), respectively. The 3-year EFS rates of low-risk group (R1), intermediate-risk group (R2), and high-risk group (R3) patients were 100%, 89.5% (95% CI, 76.5% to 95.5%), and 67.9% (95% CI, 55.4% to 77.6%), respectively. The prognosis of patients with MDD (+), stage IV cancer, SC/LH lymphoma, and high-risk sites was poor, and the 3-year EFS rates were 45.3% (95% CI, 68.6% to 19.0%), 65.7% (95% CI, 47.6% to 78.9%), 55.7% (95% CI, 26.2% to 77.5%), and 70.7% (95% CI, 48.6% to 84.6%), respectively. At the end of follow-up, one of the five patients who received maintenance therapy with VBL relapsed, and seven patients receiving anaplastic lymphoma kinase inhibitor maintenance therapy did not experience relapse.
Conclusion
This study has confirmed the poor prognostic of MDD (+), high-risk site and SC/LH, but patients with SC/LH lymphoma and MDD (+) at diagnosis still need to receive better treatment (ClinicalTrials.gov number, NCT03971305).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
- The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
- Union Hospital Affiliated to Fujian Medical University, Fuzhou, China.
- Shenzhen Children's Hospital, Shenzhen, China.
- Kunming Children's Hospital, Kunming, China.
Zitieren
APA
Chen, T., Zeng, C., Wang, J., Sun, F., Huang, J., Zhu, J., Lu, S., Liao, N., Zhang, X., Chen, Z., Yuan, X., Yang, Z., Guo, H., Yang, L., Wen, C., Zhang, W., Li, Y., Luo, X., Wu, Z., …, & Zhen, Z. (2024). Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.104
Vancouver
Chen T, Zeng C, Wang J, Sun F, Huang J, Zhu J, et al. Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study. Cancer Research and Treatment. 2024. doi:10.4143/crt.2024.104
BibTeX
@article{Chen2024,
author = {Chen, Tingting and Zeng, Chenggong and Wang, Juan and Sun, Feifei and Huang, Junting and Zhu, Jia and Lu, Suying and Liao, Ning and Zhang, Xiaohong and Chen, Zaisheng and Yuan, Xiuli and Yang, Zhen and Guo, Haixia and Yang, Liangchun and Wen, Chuan and Zhang, Wenlin and Li, Yang and Luo, Xuequn and Wu, Zelin and Yang, Lihua and Liu, Riyang and Zheng, Mincui and He, Xiangling and Sun, Xiaofei and Zhen, Zijun},
title = {Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study},
journal = {Cancer Research and Treatment},
year = {2024},
doi = {10.4143/crt.2024.104}
}
EUVIMED